Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.49 |
| ▸ | NQO2 | P16083 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | ACP3 | P15309 | 1/20 | 0.47 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29756610 | 1.00 | CYP1A2 (0.54) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL8904542 | 0.87 | CYP1A2 (0.50) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL3047898 | 0.85 | CYP1A2 (0.62) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL8903451 | 0.84 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL11396815 | 0.84 | CYP1A2 (0.47) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL27549 | 0.82 | CYP1A2 (0.54) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL5830948 | 0.81 | GPR84 (0.59) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL3196492 | 0.81 | CYP1A2 (0.58) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL29774249 | 0.81 | CYP1A2 (0.58) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A | |
| SCHEMBL9800436 | 0.81 | CYP1A2 (0.58) | CYP1A2CYP2C19CYP2C9CYP2D6MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716296-B | Efficient halogenation synthesis method of alkyl halide | 润药仁智(北京)科技有限公司 | 2023-12-12 | — | — | CN | disclosed |
| CN-113880737-B | Application of novel persulfate reagent in synthesis of asymmetric polysulfide | 安徽农业大学 | 2023-09-15 | — | — | CN | disclosed |
| CN-114716296-A | Efficient halogenation synthesis method of alkyl halide | 北京大学 | 2022-07-08 | — | — | CN | disclosed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| CN-113880737-A | Application of novel persulfur reagent in synthesis of asymmetric persulfur | 安徽农业大学 | 2022-01-04 | — | — | CN | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| CN-106518899-B | Four Boroethane class compounds of one kind and preparation method thereof | 中国科学技术大学 | 2018-10-23 | — | — | CN | disclosed |
| US-9856182-B2 | Radiofluorination method | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2018-01-02 | — | — | US | disclosed |
| CN-106518899-A | Tetraborate ethanes compound and preparation method thereof | 中国科学技术大学 | 2017-03-22 | — | — | CN | disclosed |
| US-9505753-B2 | Inhibitors of D-amino acid oxidase | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-29 | — | — | US | disclosed |
| EP-0771196-B1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5717109-A | CARBOXYCYCLOPROPYL GLYCINE DERIVATIVES; USEFUL FOR TREATMENT OF ACUTE OR CHRONIC NEURODEGENERATIVE CONDITIONS, AND AS ANTIPSYCHOTIC, ANTICONVULSANT, ANALGESIC, ANXIOLYTIC, ANTIDEPRESSANT AND ANTI-EMETIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-02-10 | — | — | US | disclosed |
| EP-0771196-A4 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 1997-09-03 | — | — | EP | disclosed |
| EP-0771196-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996007405-A1 | EXCITATORY AMINO ACID RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1996-03-14 | — | — | WO | disclosed |
| US-5480913-A | DIHYDRO-PHENANTHRENE DERIVATIVES, SIDE EFFECT REDUCTION | ARCH DEVELOPMENT CORPORATION (US) | 1996-01-02 | — | — | US | disclosed |
| EP-0363128-B1 | ANTI-ANDROGEN COMPOUNDS | ARCH DEVELOPMENT CORPORATION (US) | 1993-09-01 | — | — | EP | disclosed |
| US-5208263-A | Dihydrophenanthrene derivatives | ARCH DEVELOPMENT CORPORATION (US) | 1993-05-04 | — | — | US | disclosed |
| WO-1990003979-A2 | ANTI-ANDROGEN COMPOUNDS | ARCH DEVELOPMENT CORPORATION (US) | 1990-04-19 | — | — | WO | disclosed |
| EP-0363128-A2 | Anti-androgen compounds | ARCH DEVELOPMENT CORPORATION (US) | 1990-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | CYP1A2 2229/4885CYP2C19 3443/4885CYP2C9 3312/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | CYP1A2 2229/4885CYP2C19 3443/4885CYP2C9 3312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.